2 weeks Ago By ABMN Staff
Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS – Get Free Report ) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totalling 36,400 shares, a decline of 24.
6% from the August 31st total of 48,300 shares. Currently, 2.8% of the company’s stock are sold short.
Based on an average trading volume of 133,400 shares, the short-interest ratio is presently 0.3 days. Insider Buying and Selling at Pieris Pharmaceuticals In other Pieris Pharmaceuticals news, major shareholder Adar1 Capital Management, Llc bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 12th.
The stock was acquired at an average price of $15.88 per share, with a total value of $47,640.00.
Following the completion of the transaction, the insider now owns 129,574 shares in the company, valued at $2,057,635.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink .
Company insiders own 8.89% of the company’s stock. Analyst Ratings Changes Separately, StockNews.
com cut shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 16th. Pieris Pharmaceuticals Stock Performance PIRS remained flat at $16.16 on Friday.
26,486 shares of the company were exchanged, compared to its average volume of 13,121. The firm has a market cap of $21.33 million, a PE ratio of -1.
35 and a beta of 0.66. Pieris Pharmaceuticals has a twelve month low of $6.
20 and a twelve month high of $26.80. The firm’s fifty day simple moving average is $16.
58 and its two-hundred day simple moving average is $13.09. Pieris Pharmaceuticals ( NASDAQ:PIRS – Get Free Report ) last posted its earnings results on Wednesday, August 14th.
The biotechnology company reported ($2.76) EPS for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.
71% and a negative return on equity of 101.29%. About Pieris Pharmaceuticals ( Get Free Report ) Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications.
The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. Featured Stories Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
